1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin has been researched along with mozavaptan in 1 studies
Studies (1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin) | Trials (1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin) | Recent Studies (post-2010) (1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin) | Studies (mozavaptan) | Trials (mozavaptan) | Recent Studies (post-2010) (mozavaptan) |
---|---|---|---|---|---|
35 | 0 | 0 | 165 | 8 | 24 |
Protein | Taxonomy | 1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin (IC50) | mozavaptan (IC50) |
---|---|---|---|
Vasopressin V2 receptor | Homo sapiens (human) | 0.6373 | |
Vasopressin V1a receptor | Rattus norvegicus (Norway rat) | 3.2 | |
Vasopressin V1a receptor | Homo sapiens (human) | 1.1373 | |
Vasopressin V1b receptor | Homo sapiens (human) | 2 | |
Vasopressin V1b receptor | Rattus norvegicus (Norway rat) | 5 | |
Vasopressin V2 receptor | Rattus norvegicus (Norway rat) | 0.012 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujisawa, G; Ishikawa, S; Okada, K; Saito, T; Tsuboi, Y | 1 |
1 other study(ies) available for 1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin and mozavaptan
Article | Year |
---|---|
Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats.
Topics: Animals; Arginine Vasopressin; Benzazepines; Blood Pressure; Body Weight; Diuresis; Glomerular Filtration Rate; Liver Cirrhosis, Experimental; Male; Osmolar Concentration; Rats; Rats, Wistar; Vasopressins; Water-Electrolyte Balance | 1994 |